Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$3.3 million.

  • Fennec Pharmaceuticals' Other Working Capital Changes fell 66430.21% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 10666.32%. This contributed to the annual value of $24.8 million for FY2024, which is 2395480.77% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Other Working Capital Changes of -$3.3 million as of Q3 2025, which was down 66430.21% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Other Working Capital Changes ranged from a high of $25.2 million in Q1 2024 and a low of -$3.3 million during Q3 2025
  • Moreover, its 5-year median value for Other Working Capital Changes was -$180000.0 (2021), whereas its average is $1.7 million.
  • In the last 5 years, Fennec Pharmaceuticals' Other Working Capital Changes tumbled by 286666.67% in 2021 and then surged by 1937175.57% in 2024.
  • Fennec Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $823000.0 in 2021, then plummeted by 40.22% to $492000.0 in 2022, then fell by 14.84% to $419000.0 in 2023, then crashed by 204.3% to -$437000.0 in 2024, then crashed by 664.3% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, $2.3 million for Q2 2025, and -$636000.0 during Q1 2025.